Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05093231 2025-09-18

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05132504 2025-07-18

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06498518 2025-07-11

PRIMUS006

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT04901741 2025-06-27

OPTIMUS

Phase 2 Not yet recruiting

60 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04907851 2025-03-17

KEYNOTE-E86

Phase 2 Completed

45 enrolled 25 charts

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT05462496 2024-10-15

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03006302 2024-10-08

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Phase 2 Completed

41 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04447092 2024-04-19

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Phase 2 Active not recruiting

77 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03331562 2022-12-27

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Phase 2 Completed

24 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03723915 2022-10-05

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Phase 2 Terminated

17 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04835402 2022-03-09

EPIC-1

Phase 2 Unknown

8 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03681951 2020-07-31

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Phase 2 Terminated

8 enrolled 24 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04058964 2020-03-13

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02362048 2019-10-01

KEYNOTE144

Phase 2 Completed

77 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03432676 2019-05-30

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03634332 2019-05-07

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Phase 2 Unknown

35 enrolled

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms